RecruitMe Clinical Trial

An Open-Label, Randomized, Phase 2 Dose-Finding Study of Pacritinib in Patients with Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post- Essential Thrombocythemia Myelofibrosis Previously Treated with Ruxolitinib
Dose-Finding Study of Pacritinib in Patients With Leukemia Previously Treated With Ruxolitinib
Sponsor:CTI BioPharma
Enrolling:Male and Female Patients
Minimum Age:18 years old
IRB Number:AAAR9195
U.S. Government ID:NCT03165734
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information:

The purpose of this study is to find out what dose of pacritinib is safest and works best for participants. Pacritinib is an experimental drug, which is a drug that is being tested and is not currently approved by the Food and Drug Administration (FDA) in the US. The study will be conducted at about 85 study clinics in North America, Europe, Israel and South Korea and about 150 people participate in this study.

Do You Qualify?
Are you 18 years old?YesNo
Do you have Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocytopenia Myelofibrosis?YesNo
Do you have a life expectancy of 6 months?YesNo
Submit
Cancel
Investigator
Mark Heaney, MD, PhD
You may be eligible for this study

Place Holder




Who Can I Contact?
For more information, please contact:
Research Nurse Navigator
Email: cancerclinicaltrials@cumc.columbia.edu
Phone: 212-342-5162